171 related articles for article (PubMed ID: 8605372)
21. Use of partially mismatched related donors extends access to allogeneic marrow transplant.
Henslee-Downey PJ; Abhyankar SH; Parrish RS; Pati AR; Godder KT; Neglia WJ; Goon-Johnson KS; Geier SS; Lee CG; Gee AP
Blood; 1997 May; 89(10):3864-72. PubMed ID: 9160695
[TBL] [Abstract][Full Text] [Related]
22. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
Ogawa H; Soma T; Hosen N; Tatekawa T; Tsuboi A; Oji Y; Tamaki H; Kawakami M; Ikegame K; Murakami M; Fujioka T; Kim EH; Oka Y; Sugiyama H
Transplantation; 2002 Jul; 74(2):236-43. PubMed ID: 12151737
[TBL] [Abstract][Full Text] [Related]
23. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation.
Yu C; Storb R; Deeg HJ; Graham TC; Scheuning FG; Huss R; Seidel K; Fitzsimmons WE
Bone Marrow Transplant; 1996 Apr; 17(4):649-53. PubMed ID: 8722370
[TBL] [Abstract][Full Text] [Related]
24. Treatment of leukemia with partially matched related bone marrow transplantation.
Munn RK; Henslee-Downey PJ; Romond EH; Marciniak EJ; Fleming DR; Messino MJ; Macdonald JS; Rayens MK; Harder EJ; Phillips GL; Thompson JS
Bone Marrow Transplant; 1997 Mar; 19(5):421-7. PubMed ID: 9052906
[TBL] [Abstract][Full Text] [Related]
25. [FK506 for the prophylaxis of graft-versus-host-disease after bone marrow transplantation from HLA-genotypically mismatched unrelated donor].
Nishida T; Haneda M; Kanie T; Murata M; Hamaguchi M; Minami S; Kodera Y
Rinsho Ketsueki; 1998 Aug; 39(8):574-9. PubMed ID: 9785975
[TBL] [Abstract][Full Text] [Related]
26. Unrelated donor marrow transplantation in children.
Balduzzi A; Gooley T; Anasetti C; Sanders JE; Martin PJ; Petersdorf EW; Appelbaum FR; Buckner CD; Matthews D; Storb R; Sullivan KM; Hansen JA
Blood; 1995 Oct; 86(8):3247-56. PubMed ID: 7579422
[TBL] [Abstract][Full Text] [Related]
27. CD31 mismatching affects marrow transplantation outcome.
Grumet FC; Hiraki DD; Brown BWM ; Zehnder JL; Zacks ES; Draksharapu A; Parnes J; Negrin RS
Biol Blood Marrow Transplant; 2001; 7(9):503-12. PubMed ID: 11669217
[TBL] [Abstract][Full Text] [Related]
28. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation.
Jacobson P; Uberti J; Davis W; Ratanatharathorn V
Bone Marrow Transplant; 1998 Aug; 22(3):217-25. PubMed ID: 9720734
[TBL] [Abstract][Full Text] [Related]
29. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
[TBL] [Abstract][Full Text] [Related]
30. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
Casper J; Camitta B; Truitt R; Baxter-Lowe LA; Bunin N; Lawton C; Murray K; Hunter J; Pietryga D; Garbrecht F
Blood; 1995 May; 85(9):2354-63. PubMed ID: 7727769
[TBL] [Abstract][Full Text] [Related]
31. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan.
Yanada M; Emi N; Naoe T; Sakamaki H; Takahashi S; Hirabayashi N; Hiraoka A; Kanda Y; Tanosaki R; Okamoto S; Iwato K; Atsuta Y; Hamajima N; Tanimoto M; Kato S
Bone Marrow Transplant; 2004 Aug; 34(4):331-7. PubMed ID: 15220958
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506.
Ohashi Y; Minegishi M; Fujie H; Tsuchiya S; Konno T
Bone Marrow Transplant; 1997 Mar; 19(6):625-7. PubMed ID: 9085743
[TBL] [Abstract][Full Text] [Related]
33. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.
Van Lint MT; Uderzo C; Locasciulli A; Majolino I; Scimé R; Locatelli F; Giorgiani G; Arcese W; Iori AP; Falda M; Bosi A; Miniero R; Alessandrino P; Dini G; Rotoli B; Bacigalupo A
Blood; 1998 Oct; 92(7):2288-93. PubMed ID: 9746766
[TBL] [Abstract][Full Text] [Related]
34. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
35. Quantitative assessment of posttransplant host-specific interleukin-2-secreting T-helper cell precursors in patients with and without acute graft-versus-host disease after allogeneic HLA-identical sibling bone marrow transplantation.
Nierle T; Bunjes D; Arnold R; Heimpel H; Theobald M
Blood; 1993 Feb; 81(3):841-8. PubMed ID: 8427976
[TBL] [Abstract][Full Text] [Related]
36. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation.
Koehler MT; Howrie D; Mirro J; Neudorf S; Blatt J; Corey S; Wollman M; Kelly-Ekeroth V; Reyes J
Bone Marrow Transplant; 1995 Jun; 15(6):895-9. PubMed ID: 7581088
[TBL] [Abstract][Full Text] [Related]
37. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
38. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
Yanik G; Levine JE; Ratanatharathorn V; Dunn R; Ferrara J; Hutchinson RJ
Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426
[TBL] [Abstract][Full Text] [Related]
39. Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease.
Olson KA; West K; McCarthy PL
Pharmacotherapy; 2014 Jun; 34(6):e60-4. PubMed ID: 24700567
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
